The long-term objective of this project is to understand the regulation of FcgammaR-mediated functions such as phagocytosis and ADCC, both important defense mechanisms in cancer. Antibodies form an important link between humoral and cell-mediated immunity. The Fc region of the antigen-complexed antibody serves to activate FcR-bearing effector cells to antigenic challenge. Indeed this basic principle has been elegantly exploited by cancer biologists to develop antibody-mediated therapeutic approaches. In murine models of antibody therapy, it has been clearly demonstrated that anti-tumor antibodies work by recruiting and activating Fc receptor-bearing effector cells, predominantly monocytes/macrophages, leading to the destruction of the tumor cells. Thus, it is critical to understand the molecular details of macrophage FcgammaR expression and function to develop strategies to enhance the efficacy of anti-tumor antibodies. Our work in the last several years has revealed two critical findings, i.e that Fc receptor-mediated macrophage functions are critically regulated by phosphatases through their influence on Akt, and that the expression of the activating and the inhibiting Fc receptors is differentially regulated by mediators present in the surrounding milieu leading to altered functional outcomes. Thus in the current grant proposal we propose the following three specific aims: 1) to examine the unexpected role of Akt on Fcgamma receptor- mediated macrophage activation events leading to phagocytosis and ADCC against antibody-coated tumor cells, 2) to examine the influence of Akt on phagocytosis-associated inflammatory events such as cytokine production and the generation of reactive oxygen species, and 3) to investigate the influnec of TGFbeta and CpG ODN on Fcgamma receptor expression and function. A thorough understanding of monocyte/macrophage Fcgamma receptor expression and function will likely identify better immunotherapeutic strategies to enhance the efficacy of monoclonal antibodies in cancer therapy. Given our interactions with the other Projects and the Cores of this Program Project, we are optimally poised to unravel the molecular details of monocyte/macrophage biology as it pertains to Fc receptor-mediated functional outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA095426-07
Application #
7682168
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
7
Fiscal Year
2008
Total Cost
$238,366
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Dai, Hong-Sheng; Caligiuri, Michael A (2018) Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells. Front Immunol 9:183
Byrd, John C; Smith, Stephen; Wagner-Johnston, Nina et al. (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9:13023-13035
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Olaverria Salavaggione, Gonzalo N; Duggan, Megan C; Carson, William E (2018) Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. Melanoma Res 28:390-397
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
Latchana, Nicholas; DiVincenzo, Mallory J; Regan, Kelly et al. (2018) Alterations in patient plasma microRNA expression profiles following resection of metastatic melanoma. J Surg Oncol 118:501-509
Chan, Wing Keung; Kang, Siwen; Youssef, Youssef et al. (2018) A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma. Cancer Immunol Res 6:776-787
Lai, Xiulan; Stiff, Andrew; Duggan, Megan et al. (2018) Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors. Proc Natl Acad Sci U S A 115:5534-5539

Showing the most recent 10 out of 294 publications